S&P 500   5,250.85 (+0.04%)
DOW   39,767.80 (+0.02%)
QQQ   444.42 (-0.09%)
AAPL   170.98 (-1.34%)
MSFT   420.41 (-0.24%)
META   486.27 (-1.54%)
GOOGL   150.50 (-0.25%)
AMZN   180.28 (+0.25%)
TSLA   176.57 (-1.81%)
NVDA   906.00 (+0.39%)
NIO   4.61 (-1.28%)
AMD   181.21 (+0.90%)
BABA   72.49 (+1.26%)
T   17.61 (+0.34%)
F   13.25 (+1.45%)
MU   118.18 (-0.81%)
CGC   9.70 (+1.57%)
GE   175.26 (-2.70%)
DIS   122.67 (+1.40%)
AMC   3.70 (-14.75%)
PFE   27.88 (+0.36%)
PYPL   67.20 (+0.95%)
XOM   115.76 (+0.69%)
S&P 500   5,250.85 (+0.04%)
DOW   39,767.80 (+0.02%)
QQQ   444.42 (-0.09%)
AAPL   170.98 (-1.34%)
MSFT   420.41 (-0.24%)
META   486.27 (-1.54%)
GOOGL   150.50 (-0.25%)
AMZN   180.28 (+0.25%)
TSLA   176.57 (-1.81%)
NVDA   906.00 (+0.39%)
NIO   4.61 (-1.28%)
AMD   181.21 (+0.90%)
BABA   72.49 (+1.26%)
T   17.61 (+0.34%)
F   13.25 (+1.45%)
MU   118.18 (-0.81%)
CGC   9.70 (+1.57%)
GE   175.26 (-2.70%)
DIS   122.67 (+1.40%)
AMC   3.70 (-14.75%)
PFE   27.88 (+0.36%)
PYPL   67.20 (+0.95%)
XOM   115.76 (+0.69%)
S&P 500   5,250.85 (+0.04%)
DOW   39,767.80 (+0.02%)
QQQ   444.42 (-0.09%)
AAPL   170.98 (-1.34%)
MSFT   420.41 (-0.24%)
META   486.27 (-1.54%)
GOOGL   150.50 (-0.25%)
AMZN   180.28 (+0.25%)
TSLA   176.57 (-1.81%)
NVDA   906.00 (+0.39%)
NIO   4.61 (-1.28%)
AMD   181.21 (+0.90%)
BABA   72.49 (+1.26%)
T   17.61 (+0.34%)
F   13.25 (+1.45%)
MU   118.18 (-0.81%)
CGC   9.70 (+1.57%)
GE   175.26 (-2.70%)
DIS   122.67 (+1.40%)
AMC   3.70 (-14.75%)
PFE   27.88 (+0.36%)
PYPL   67.20 (+0.95%)
XOM   115.76 (+0.69%)
S&P 500   5,250.85 (+0.04%)
DOW   39,767.80 (+0.02%)
QQQ   444.42 (-0.09%)
AAPL   170.98 (-1.34%)
MSFT   420.41 (-0.24%)
META   486.27 (-1.54%)
GOOGL   150.50 (-0.25%)
AMZN   180.28 (+0.25%)
TSLA   176.57 (-1.81%)
NVDA   906.00 (+0.39%)
NIO   4.61 (-1.28%)
AMD   181.21 (+0.90%)
BABA   72.49 (+1.26%)
T   17.61 (+0.34%)
F   13.25 (+1.45%)
MU   118.18 (-0.81%)
CGC   9.70 (+1.57%)
GE   175.26 (-2.70%)
DIS   122.67 (+1.40%)
AMC   3.70 (-14.75%)
PFE   27.88 (+0.36%)
PYPL   67.20 (+0.95%)
XOM   115.76 (+0.69%)
NASDAQ:BTTX

Better Therapeutics (BTTX) Stock Price, News & Analysis

$0.01
+0.00 (+4.65%)
(As of 11:56 AM ET)
Today's Range
$0.0129
$0.0160
50-Day Range
$0.01
$0.22
52-Week Range
$0.01
$1.61
Volume
549,244 shs
Average Volume
6.78 million shs
Market Capitalization
$673,110.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00

Better Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
46,053.8% Upside
$6.00 Price Target
Short Interest
Bearish
8.29% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.51mentions of Better Therapeutics in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.86) to ($0.56) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.02 out of 5 stars

BTTX stock logo

About Better Therapeutics Stock (NASDAQ:BTTX)

Better Therapeutics, Inc., a prescription digital therapeutics company, develops a form of cognitive behavioral therapy to address the causes of cardiometabolic diseases. The company's lead product candidate is BT-001, an investigational PDT platform to treat type 2 diabetes. It also develops software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions. In addition, the company's clinical development candidates are intended to treat cardiometabolic diseases, including type 2 diabetes, hypertension, hyperlipidemia, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and chronic kidney disease. Its product pipeline also includes BT-002, which intends glycemic control for hypertension; BT-003 to reduce LDL cholesterol in patients with hyperlipidemia; and BT-004, which intends to explore the impact of treatment on liver health in patients with non-alcoholic steatohepatitis/non-alcoholic fatty liver disease. The company was founded in 2015 and is headquartered in San Francisco, California.

BTTX Stock Price History

BTTX Stock News Headlines

Better Therapeutics (BTTX) Set to Announce Earnings on Thursday
The AI Defense Stock Set to Soar
To protect our interests, The Pentagon has partnered with this small AI defense contractor - creating some of the most powerful AI defenses ever made.
Dow Dips Over 100 Points; Dick's Sporting Goods Earnings Top Views
The AI Defense Stock Set to Soar
To protect our interests, The Pentagon has partnered with this small AI defense contractor - creating some of the most powerful AI defenses ever made.
CAH Feb 2024 107.000 put
Biora Therapeutics Provides Outlook for 2024
See More Headlines
Receive BTTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Better Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
3/28/2024
Next Earnings (Estimated)
4/04/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Health services
Sub-Industry
N/A
Current Symbol
NASDAQ:BTTX
Fax
N/A
Employees
54
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$6.00
High Stock Price Target
$9.00
Low Stock Price Target
$3.00
Potential Upside/Downside
+46,053.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$-39,760,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($0.04) per share

Miscellaneous

Free Float
24,233,000
Market Cap
$648,180.00
Optionable
Optionable
Beta
2.35
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Mr. David P. Perry M.B.A. (Age 56)
    Co-Founder & Executive Chairman
    Comp: $260k
  • Mr. Frank L. Karbe (Age 56)
    CEO, Interim CFO, President & Director
    Comp: $533.37k
  • Dr. Mark A. Berman M.D. (Age 49)
    Chief Medical Officer
    Comp: $573.75k
  • Ms. Kristin Wynholds (Age 52)
    Chief Product Officer
    Comp: $519.07k
  • Mr. Andres Camacho
    Senior VP of Technology & Head of Engineering
  • Ms. Angela Willis
    Senior Vice President of Market Access
  • Ms. Jessica Meng
    Chief Commercial Officer
  • Leslie Miller
    Controller

BTTX Stock Analysis - Frequently Asked Questions

Should I buy or sell Better Therapeutics stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Better Therapeutics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" BTTX shares.
View BTTX analyst ratings
or view top-rated stocks.

What is Better Therapeutics' stock price target for 2024?

3 equities research analysts have issued twelve-month price objectives for Better Therapeutics' stock. Their BTTX share price targets range from $3.00 to $9.00. On average, they predict the company's stock price to reach $6.00 in the next year. This suggests a possible upside of 46,053.8% from the stock's current price.
View analysts price targets for BTTX
or view top-rated stocks among Wall Street analysts.

How have BTTX shares performed in 2024?

Better Therapeutics' stock was trading at $0.1950 at the start of the year. Since then, BTTX stock has decreased by 93.3% and is now trading at $0.0130.
View the best growth stocks for 2024 here
.

Are investors shorting Better Therapeutics?

Better Therapeutics saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 2,560,000 shares, an increase of 20.2% from the February 29th total of 2,130,000 shares. Based on an average trading volume of 6,410,000 shares, the short-interest ratio is presently 0.4 days. Approximately 8.3% of the shares of the stock are sold short.
View Better Therapeutics' Short Interest
.

When is Better Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024.
View our BTTX earnings forecast
.

Who are Better Therapeutics' major shareholders?

Better Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include MMCAP International Inc. SPC (0.71%), Vanguard Group Inc. (0.40%), Vanguard Group Inc. (0.40%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Andrew J Armanino, David P Perry, Elder Granger, Frank Karbe, Geoffrey M Parker, Kevin J Appelbaum, Mark A Berman, Mark Heinen and Risa J Lavizzo-Mourey.
View institutional ownership trends
.

How do I buy shares of Better Therapeutics?

Shares of BTTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BTTX) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners